Offer - Urjas Oil for just ₹ 1
Caligno is an allopathic medicine The correct dosage of Caligno depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Caligno is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Caligno safe for pregnant women?
Caligno rarely shows harmful effects in in pregnant ladies. Even if it does, the effects are mild
Is the use of Caligno safe during breastfeeding?
Side effects of Caligno for breastfeeding are little to none, so you can take it without doctor's advice.
What is the effect of Caligno on the Kidneys?
Caligno rarely affects the kidneys.
What is the effect of Caligno on the Liver?
Caligno is rarely harmful for the liver.
What is the effect of Caligno on the Heart?
Caligno may have mild side effects on the heart. Most people will never see any effect on the heart.
Caligno should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Caligno unless your doctor advises you to do so -
Is this Caligno habit forming or addictive?
Forming a habit of Caligno has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Caligno as you may feel sleepy.
Is it safe?
Caligno is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
Caligno is unable to treat or cure mental disorders.
Interaction between Food and Caligno
Some foods when eaten with Caligno can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Caligno
Due to lack of research, there is no information about the side effects of taking Caligno with alcohol.
According to an FDA warning published in 2014, a 2% solution of Caligno should not be used in infants and young children (5 months to 3.5 years old), as too much application of Caligno or accidental swallowing may cause serious brain injury, seizures, and heart problems. Therefore, for treating teething pain, one must take the advice of their doctor and follow his recommendations completely.
Caligno is a local anesthetic agent which prevent the sensation of pain. It works by inhibiting the pain signal from the nerves to the brain lead to decrease pain sensation and discomfort arising due to skin irritation, sunburn or other medical conditions.
Yes, Caligno is used topically for producing an anesthetic effect (Prevent pain) on the irritated or inflamed mucous membranes of mouth and pharynx. It is also used for minimizing gagging during X-ray procedure and dental impressions.
No, Caligno is not a narcotic. It is a local anesthetic agent which is used to cause numbness and block pain. Narcotics are the natural products like opium and its derivatives, heroin, coca leaf, and cannabis, synthetic drugs like pethidine, methadone, codeine, and morphine. These are also prescription drugs and must be taken cautiously as these can cause an addiction.
Caligno is available as a topical solution, gel, patch, spray, and injection. It is a prescription drug, hence, one must not use it on his/her own. It should be taken under medical supervision only. It should be stored away from the reach of children and pets.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xylocaine (lidocaine HCl)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 366
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 771-775